Literature DB >> 11426974

Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase.

M Keith Bechtel1, B Bonavida.   

Abstract

OBJECTIVES: Indirect evidence suggests that estrogen and progesterone are involved in the etiology of ovarian cancer (Oca). Estrogen and progesterone are also thought to modulate nitric oxide (NO) in human ovarian tumor tissue via regulation of inducible nitric oxide synthase (iNOS). Objectives in this study were: (1) to investigate the effects of 17beta-estradiol (E(2)) and progesterone (P(4)) on Oca cell proliferation employing elevated hormone concentrations occurring within the microenvironment of the ovary, and (2) to determine whether E(2) or P(4) affects iNOS expression and NO generation in Oca cells.
METHODS: Proliferation assays assessed the effects of E(2) and P(4) on cell growth in three human Oca cell lines (HOC-7, OVCAR-3, SKOV-3). Reverse transcriptase polymerase chain reaction was used to assess mRNA expression and Western blots to determine protein levels. NO generation was determined via the Griess reaction.
RESULTS: Elevated E(2), P(4), or E(2) plus P(4) (E + P), significantly inhibited HOC-7 cells and OVCAR-3 cells, but not SKOV-3 cells. E(2) at 10 microM downregulated iNOS expression and significantly reduced NO production in HOC-7 cells, while 10 microM P(4) or 10 microM E + P increased iNOS expression and NO production. Conclusions. Our findings demonstrate that elevated E(2), P(4), or E + P results in significant growth inhibition of Oca cells, and we propose a role for iNOS and NO in how these hormones modulate their activities in Oca cells. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11426974     DOI: 10.1006/gyno.2001.6221

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  Dynamics of the primate ovarian surface epithelium during the ovulatory menstrual cycle.

Authors:  Jay W Wright; Leigh Jurevic; Richard L Stouffer
Journal:  Hum Reprod       Date:  2011-03-18       Impact factor: 6.918

2.  Genetic variation in the progesterone receptor gene and ovarian cancer risk.

Authors:  Kathryn L Terry; Immaculata De Vivo; Linda Titus-Ernstoff; Patrick M Sluss; Daniel W Cramer
Journal:  Am J Epidemiol       Date:  2005-03-01       Impact factor: 4.897

Review 3.  Progesterone action in breast, uterine, and ovarian cancers.

Authors:  Caroline H Diep; Andrea R Daniel; Laura J Mauro; Todd P Knutson; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2015-01-13       Impact factor: 5.098

4.  Progesterone induces progesterone receptor gene (PGR) expression via rapid activation of protein kinase pathways required for cooperative estrogen receptor alpha (ER) and progesterone receptor (PR) genomic action at ER/PR target genes.

Authors:  Caroline H Diep; Hannah Ahrendt; Carol A Lange
Journal:  Steroids       Date:  2016-09-15       Impact factor: 2.668

5.  Estradiol 17β and its metabolites stimulate cell proliferation and antagonize ascorbic acid-suppressed cell proliferation in human ovarian cancer cells.

Authors:  Hui-Hui Li; Ying-Jie Zhao; Yan Li; Cai-Feng Dai; Sheikh O Jobe; Xing-Sheng Yang; Xing-Fu Li; Manish S Patankar; Ronald R Magness; Jing Zheng
Journal:  Reprod Sci       Date:  2013-06-11       Impact factor: 3.060

6.  Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells.

Authors:  Caroline H Diep; Nathan J Charles; C Blake Gilks; Steve E Kalloger; Peter A Argenta; Carol A Lange
Journal:  Cell Cycle       Date:  2013-04-10       Impact factor: 4.534

7.  Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.

Authors:  Alicia A Goyeneche; Rubén W Carón; Carlos M Telleria
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

8.  Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.

Authors:  Chelsea R Tieszen; Alicia A Goyeneche; BreeAnn N Brandhagen; Casey T Ortbahn; Carlos M Telleria
Journal:  BMC Cancer       Date:  2011-05-27       Impact factor: 4.430

Review 9.  Antiprogestins in gynecological diseases.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reproduction       Date:  2014-09-24       Impact factor: 3.906

Review 10.  Estrogen, progesterone and epithelial ovarian cancer.

Authors:  Shuk-Mei Ho
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.